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study protocol of a non-inferiority
randomized trial
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Abstract
Background: The majority of patients with depressive disorders are treated by general practitioners (GPs) and are
prescribed antidepressant medication. Patients prefer psychological treatments but they are under-used, mainly due
to time constraints and limited accessibility. A promising approach to deliver psychological treatment is blended
care, i.e. guided online treatment. However, the cost-effectiveness of blended care formatted as an online
psychological treatment supported by the patients’ own GP or general practice mental health worker (MHW) in
routine primary care is unknown. We aim to demonstrate non-inferiority of blended care compared with usual care
in patients with depressive symptoms or a depressive disorder in general practice. Additionally, we will explore the
real-time course over the day of emotions and affect, and events within individuals during treatment.
Methods: This is a pragmatic non-inferiority trial including 300 patients with depressive symptoms, recruited by
collaborating GPs and MHWs. After inclusion, participants are randomized to either blended care or usual care in
routine general practice. Blended care consists of the ‘Act and Feel’ treatment: an eight-week web-based program
based on behavioral activation with integrated monitoring of depressive symptomatology and automatized
feedback. GPs or their MHWs coach the participants through regular face-to-face or telephonic consultations with at
least three sessions. Depressive symptomatology, health status, functional impairment, treatment satisfaction, daily
activities and resource use are assessed during a follow-up period of 12 months. During treatment, real-time
fluctuations in emotions and affect, and daily events will be rated using ecological momentary assessment. The
primary outcome is the reduction of depressive symptoms from baseline to three months follow-up. We will
conduct intention-to-treat analyses and supplementary per-protocol analyses.
Discussion: This trial will show whether blended care might be an appropriate treatment strategy for patients with
depressive symptoms and depressive disorder in general practice.
Trial registration: Netherlands Trial Register: NTR4757; 25 August 2014. http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=4757. (Archived by WebCite® at http://www.webcitation.org/6mnXNMGef)
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Background
Depressive disorders are common. Up to 15% of people
in high-income countries experience a major depressive
episode at least once in their lifetime [1, 2] Depressive
disorders cause high personal and economic burden of
disease through their effects on many aspects of life such
as participation and functioning [3–5]
The majority of patients (65% to 80%) with mild and
moderate depression are treated by general practitioners
(GPs) [6–11]. GPs in many countries including the
Netherlands are recommended to use a (collaborative)
stepped care management approach in the treatment of
depression with antidepressants appearing only in the
second step [12, 13]. Nevertheless, in routine general
practice an estimated 70% of cases are primarily treated
with antidepressants worldwide [9, 14–16]. This is wor-
risome as there is increasing evidence that antidepressants,
while bringing about side effects, are ineffective in patients
with mild to moderate depressive disorders which are
particularly common in general practice [17–19]. This con-
trasts with psychological treatments that have convincingly
shown effectiveness in these patients [20]. Moreover, most
patients prefer psychological treatment [21].
Clear barriers for the implementation of psychological
treatment in general practice exist. First, most GPs have
too little time and experience to offer psychological
treatment themselves [22, 23]. Second, referral for psy-
chological treatment is hampered by limited accessibility
due to practical barriers, such as high costs of treatment,
limited availability of trained professionals and transpor-
tation issues [22, 24, 25]. Next, patients may experience
emotional barriers such as feared stigmatization [26].
Referral by GPs to web-based programs for the treat-
ment of depression circumvents these problems effectively
by providing direct availability of psychological treatment
at home. Several systematic reviews demonstrated the
effectiveness of online psychological treatment in the
treatment of depression [27–29]. Interventions without
therapist guidance, however, showed small mean effect
size and low adherence. In contrast, web-based interven-
tions guided by a therapist (blended care) displayed rela-
tively large mean effect size and better adherence [27–29],
even comparable to face-to-face psychological treatment
[30, 31]. Better adherence to treatment is important also
for psychological interventions, as it is associated with
greater response to treatment [32]. Therefore, guidance
seems essential in the online treatment of depression.
Importantly, it can be delegated to less trained or less
experienced professionals (i.e. task-sharing) [33].
In previous trials on blended care in general practice,
experienced professionals such as clinical psychologists
or psychiatrist guided the patients [34–42]. In none of
these studies were participants guided by their own GP
or mental health worker (MHW). This may impair the
generalizability of the results of these studies to Dutch
general practice or similar settings. MWHs support
primary care in delivering good quality mental health
care by providing brief and simplified psychological
treatment, blended care or self-help [43, 44]
In previous studies mainly online psychological inter-
ventions based on cognitive behavioral therapy (CBT)
have been studied [38, 42, 45–47]. In a recent study be-
havioral activation has been shown as effective and more
cost-effective compared to CBT [48] and it has been
experienced as less complicated and more accessible to
patients and therapists [49]. MHWs can learn this tech-
nique relatively quickly and its effectiveness is compar-
able to behavioral activation delivered by more specialist
staff with more training [49]. Therefore in this trial we
evaluate a blended behavioral activation treatment (guided
‘Act and Feel’ treatment).
Blended care has been expected to reduce costs, be-
cause part of the psychological treatment is provided
online. However, a limited number of studies assessed
the cost-effectiveness of blended care in general
practice [50, 51].
To our knowledge, this is the first study investigating
the effectiveness and cost-effectiveness of a blended be-
havioral activation treatment for depressive symptoms
and disorders as performed in routine general practice.
Methods
Study design and aims
This study is a pragmatic, two-arm non-inferiority ran-
domized controlled trial with an economic evaluation in
general practice. The primary aim is to study the short-
term (i.e. three months) effectiveness of a blended be-
havioral activation treatment compared to care as usual
(CAU) for patients with depressive symptoms or disor-
ders in general practice. Secondary aims include the
short- and long-term (i.e. 12 months) cost-effectiveness
and effects of blended care on daily activities, treatment
satisfaction, medication use and other related resource
use. In addition, we will explore the effects of the
blended behavioral activation treatment and CAU on the
course of real-time experiences of emotion, affect and
events over the day.
Participants
Adults (18 years or over) with a GP diagnosis of depres-
sive symptoms or a depressive disorder for whom the
GP considers a next step in the treatment of depression
will be included [12]. Patients who fulfill the following
criteria will be excluded: a) severe depression requiring
prompt referral to specialized mental health service ac-
cording to the GP (e.g. acute suicidality); b) current/past
severe mental illness: schizophrenia, psychotic episode,
bipolar disorder, depression with psychotic features; c)
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current anxiety disorder as primary diagnosis; d) current
substance abuse (alcohol, drugs); e) current psycho-
logical treatment for depression; such as (online) cogni-
tive behavioral therapy; f ) no access to internet; g)
insufficient computer skills; h) insufficient proficiency of
Dutch language.
Study setting and recruitment
This trial will be conducted in approximately 45 general
practices in the Netherlands, located both in cities and in
villages. This is a closed trial, i.e. GPs and MHWs recruit
participants among their registered patients only. In-
formed consent will be obtained from each patient. Base-
line assessments include the Structured Clinical Interview
for DSM-IV disorders I (SCID-I). Modules A (mood
episode), D (mood disorders) and F (anxiety disorders)
allowing for diagnosing depressive disorders and anxiety
disorders. The before-mentioned exclusion criteria are
verified using the screening questions of the SCID-I; if
screened positive than the total concerning section is ad-
ministered. A trained interviewer telephonically conducts
the SCID. Agreement between telephonic and face-to-face
assessment is excellent (90% agreement) [52].
Randomization
Sequence generation and allocation
After baseline assessment participants are 1:1 randomly
assigned to one of the treatment groups, stratified by
sex, diagnosis (depressive symptoms or depressive dis-
order) and general practice (availability of a MHW). The
randomization sequence is computer-generated with
randomly varying block sizes and is concealed by an in-
dependent research department. After randomization,
the researchers inform the general practice about the
treatment allocation. The GP/MHW shares this infor-
mation with the participant during the follow-up con-
sultation. This trial is single-blinded, i.e. the treatment
allocation is concealed from the outcome assessor and
participants are asked not to reveal the treatment alloca-
tion (Fig. 1).
Guided ‘act and feel’ treatment
The guided ‘Act and Feel’ treatment is an online self-
management program blended with direct contacts
(face-to-face or telephonic) with a MHW [53, 54]. The
content of Act and Feel is based on the face-to-face
behavioral activation by Lewinsohn [55] and focuses on
depressive symptoms. Behavioral activation is based on
the behavioral theory stating that depressive behavior is
a consequence of low rates of response-contingent posi-
tive reinforcement [55]. Therefore, behavioral activation
concentrates on activating individuals by increasing ac-
tivities that are potentially reinforcing for the individual.
‘Act and Feel’ consists of eight modules with integrated
monitoring of depressive symptomatology (including
suicidality) and automatized feedback in a secure online
environment. First, it provides psycho-education about
depression and the rationale behind behavioral activa-
tion. Second, participants are given insight in their daily
mood and behavior/activities using daily activity mood
monitoring. Preplanned potential pleasurable activities
are mood-independent increased to increase the sense of
satisfaction and enhance mood in the long term. There
is additionally attention for the role of avoidant behavior
in depression and how to turn this to proactive behavior.
Finally, it concludes with the development of a personal
relapse prevention strategy.
Every module has a fixed structure, starting with a vis-
ual analogue scale (VAS) mood assessment (on a Likert
scale from 1 to 10); the rationale of that module and
specific exercises and it concludes with a summary and
evaluation of that module. The ‘Act and Feel’ treatment
provides automatically produced graphs of self-ratings
mood score and depressive symptomatology.
Guidance
The MHW supports the participants with consultations
of a targeted 30 min at two, four and six weeks. The
purposes of these consultations are to motivate and sup-
port the participants during the activation process and
to enhance adherence. In addition, participants receive
e-mail reminders when inactive on the online environ-
ment for two weeks. The MHWs who guide Act and
Feel follow a one-day training session on guidance of
Act and Feel and behavioral activation and on-demand
supervision of cases by the psychologist research assist-
ant. Before implementation of this treatment, the usabil-
ity of the ‘Act and Feel’ treatment was evaluated in a
pilot study with twenty healthy volunteers. By means of
this feedback the treatment was adjusted and after ad-
justment retested in a second pilot.
Care as usual
The control group receives CAU for depression, left at
the discretion of the GP. Patients with depressive disor-
ders in routine usual general practice care are offered
mostly pharmacological treatment and receive alongside
some psychological treatment, such as non-directive
counseling [56, 57]. We will not interfere with CAU but
document it carefully. Nevertheless, GPs (or delegated to
the MHW) are asked to plan consultations (telephonic
or face-to-face) with the participant at two, four and six
weeks as recommended by the guideline of the Dutch
College of GPs thus mirroring the intervention arm [12].
In addition, patients are monitored for depressive symp-
tomatology and acute suicidality.
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Concomitant treatments
Given the trial’s pragmatic nature, the aim is to quantify
the real life difference in the course of depressive symp-
toms between blended behavioral activation and usual
care. Consequently, all participants in both arms are
allowed to continue or to start any medical or non-
medical concomitant treatment, except for psychological
treatment, which we ask not to offer in the intervention
group during the first three months. For both groups,
the use of all forms of formal health care during the trial
is carefully documented.
Participant timeline and assessments
Both clinical and economical outcomes are measured
(Table 1). Interviewer-rated assessments are performed
telephonically (i.e. SCID-I and HRSD-17) and the online
self-report assessments through an online environment
(ResearchOnline®). Follow-up assessments are at 3, 6
and 12 months.
Random real-time assessments will be done in the first
ten weeks of participation. In addition to the assess-
ments, all patients are monitored for severe depression
and acute suicidality by filling in the self-report ques-
tionnaire QIDS weekly during ten weeks.
Outcomes
Primary outcome
The primary outcome is the reduction of depressive
symptoms from baseline to three months follow-up, as
measured with the Hamilton Depression Scale 17-items
(HRSD-17) [58–60]. This is a clinician-rated scale con-
sisting of 17 items. This scale has been widely used in
clinical trials and serves as gold standard for assessment
of depression. It has been found valid and reliable meas-
urement outcome with a higher inter-rater reliability
and test-retest reliability [59, 61].
Secondary outcomes
Depression related outcomes
The reduction of depressive symptoms on the HRSD-17
is assessed from baseline to 12 months of follow-up.
Additionally, response defined as a 50% reduction on the
HRSD-17 is evaluated at 3 and 12 months. Furthermore,
depressive symptoms are assessed weekly using the self-
reported measurement Quick Inventory of Depressive
symptoms self-reported 16 items (QIDS-SR 16). The
QIDS-SR 16 are used to monitor depressive symptoms
and to signal acute suicidality and severe depression dur-
ing the first ten weeks of treatment. When exceeding the
threshold of severe depression (i.e. HRSD-17 score 16 or
higher) or acute suicidality (i.e. score of 2 or 3 on the
suicidality item of the QIDS-R), all patients receives an
automatic message to contact their GP and MHW and
the researcher informs the GP.
Treatment satisfaction
Treatment satisfaction is assessed using a self-developed
questionnaire, consisting of five items. Each question is
Table 1 Overview of the follow-up assessments of the participants
Measures Description Baseline Week 1–10 3 months 6 months 12 months
HRSD-17 Depressive symptom rating X X X
EMA Daily real time ratings of emotion, affect
and events
X
SCID-I Diagnosis of current depressive disorder X
QIDS-16 Depressive symptoms rating X
WHODAS-II Functional impairment and activity limitation X X X
EQ-5D Health status X X X
Daily activity section of Leidsche
Rijn Health Questionnaire
Regular daily activities X X X
Treatment satisfaction X X
TIC-P Direct and indirect costs X X X
Demographics Socio-demographic characteristics X
Resource use Medication use, number of referrals and
GP consultations
X
HRSD-17: Hamilton Rating Scale for Depression, 17 items
EMA: ecological momentary assessments
SCID-I: Structured Clinical Interview for DSM disorders
QIDS-16: quick inventory of depressive symptomatology, 16 items
WHODAS-II: WHO Disability Schedule 2.0
EQ-5D: EuroQol five dimensions questionnaire
TIC-P: Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness
GP: general practitioner
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scored on a Likert-type scale from 1 to 4. The question-
naire addresses overall service satisfaction; i.e. satisfac-
tion with treatment, recommendation of treatment,
satisfaction about effectiveness of treatment and willing-
ness to repeat treatment if needed. This questionnaire is
shown in Additional file 1.
Health status
General health status is assessed with the EuroQol (EQ-
5D), which is a validated self-administered questionnaire
that contains a descriptive section and a valuation sec-
tion. The descriptive section consists of five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each of these five dimensions has
three levels of severity: no problems, some/moderate
problems and extreme problems. Values of the five di-
mensions are linearly transformed into one single score,
ranging from 0 to 1 (lower scores represent more prob-
lems). The valuation section of the EQ-5D contains a
visual analogue scale; this vertical visual scale ranges be-
tween ‘best imaginable health state = perfect health’
(score of 100) and ‘worst imaginable health state = death’
(score of 0). The EQ-5D valuation section has been
shown to be efficient and easy to use [62].
Functional impairment and activity limitations
Functional impairment and activity limitations are
assessed using the 12-item self-report World Health
Organization Disability Assessment Schedule 2.0 (WHO-
DAS 2.0). The WHODAS 2.0 is based on the conceptual
Fig. 1 Outline of inclusion, baseline assessment, and randomization and follow-up assessmentsGP: general practitioner. SCID-I: Structured Clinical
Interview for DSM disorders. HRSD-17: Hamilton Rating Scale for Depression, 17 items. EMA: ecological momentary assessments. QIDS-16: quick
inventory of depressive symptomatology, 16 items. WHODAS-II: WHO Disability Schedule 2.0. EQ-5D: EuroQol five dimensions questionnaire. TIC-P:
Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness
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framework of the International Classification of Func-
tioning, Disability and Health (ICF). It provides a
global measure of disability and 7 domain-specific
scores. It assesses health and disability on six dimen-
sions, namely cognition, mobility, self-care, getting
along, life activities and participation. WHODAS 2.0
has been validated in 1119 patients across 7 European
centers with 13 chronic conditions and it has been
shown to have good metric properties [63]
Daily activities
Daily activities are assessed using part of the Health
Questionnaire of the Utrecht Health project [64] This
part of the questionnaire assesses daily activity level dur-
ing a regular week in the past months, i.e. the kind and
duration of these activities. The blended care treatment
focuses on activating participants, by increasing their po-
tential pleasurable activities. By assessing daily activities
we study a potential prognostic mediating factor in the
recovery of depression.
Ecological momentary assessment (EMA)
We will capture real-time momentary ratings of cogni-
tions as well as affect and emotions with so-called
Ecological Momentary Assessment (EMA). Compared to
conventional questionnaires, potential advantages of
prospective precise measurement with EMA are less re-
call bias and increased detection of vulnerable patients
with adverse disease trajectories [65].
Specifically, using a smart phone application called
‘DE Free’ (Bockting, used software TEMPEST, Batalas
& Markopoulos) (Fig. 2), auditory cue signals will be
sent to participants’ cellphones. Thereupon, partici-
pants will be asked to rate their momentary states.
These include an appraisal of positive affect (i.e. being
cheerful, content, and energetic) and negative affect
(i.e. feeling gloomy, nervous, insecure, lonely, irritated,
helpless, and guilty), and activity levels (i.e. being active,
pleasantness of activity, and energy involved in per-
forming activity). Momentary states are rated on visual
analogue scales, which are either numerical and ranging
from 0 to 100 or ordinal and ranging from e.g. “not at
all” to “very much”. Furthermore, participants will be
asked to indicate the specific activities they were under-
taking and the specific situation they were in while rat-
ing these momentary states (e.g. being at home and
doing household chores). Participants will be asked to
rate their momentary states in the following time
schedule: every other day, 5 times per day, over the
course of a 10-week period. Auditory signals will be
sent at random moments during the following time in-
tervals: equally spread between 8.30 a.m. and 7.30 p.m.
Resource use
Costs related to the intervention
To calculate costs related to the internet treatment, we
include costs of running the website platform and costs
of the guidance by the GP or MHW.
Direct and indirect costs
We will measure health care costs in general (direct
costs) as well as productivity losses (indirect costs) with
the revised version of the Trimbos and iMTA Question-
naires on Costs Associated with Psychiatric Illness (TiC-
P) [66, 67]. Direct costs are measured by investigating,
which contact with health professionals has occurred
and which type of medication has been prescribed.
Indirect costs are measured by work absenteeism and re-
duced productivity. The TiC-P questions cover the pre-
vious six months; it is administrated at 6 and 12 months
follow-up.
Sample size
The sample size is based on demonstrating non-
inferiority of blended care compared to usual care for
the primary outcome, i.e. the reduction on HRSD-17
from baseline to three months follow-up. An acceptable
non-inferiority margin has been defined as the max-
imum clinically irrelevant difference between treatments
[68]. The non-inferiority margin is set to be the half of
minimal clinical important difference of 3 points on the
HRSD-17 scale as advised by the FDA [60, 69, 70]; i.e. a
non-inferiority margin of 1.5 points at the HRSD-17
(0.31 SD). The sample size was calculated with one-
sided t-test with a power of 80% (α = 0.025) to detect a
non-inferiority margin of 1.5. We compensated for an
expected loss to follow-up of 20%. We adjusted for co-
variance, as advised to reduce required sample sizes and
costs [71, 72]. In this correction we assumed a correl-
ation coefficient (ρ) of 0.5, as recommended when the
correlation coefficient is unknown [71, 73]. The number
of participants needed is then corrected with design fac-
tor (1 − ρ2), where ρ is the correlation coefficient. This
resulted in a calculated design factor of 0.75. The final
number calculated necessary to complete the trial is 151
participants per condition (a total of N = 302).
Statistical methods
First, we will compare demographic characteristics of the
trial population, to assure whether the randomization pro-
cedure has been successful.
The principle analysis will follow an intention-to-treat
(ITT) strategy including all patients analyzed according
to their randomized group. Supplementary analyses will
be done on a ‘per protocol’ basis, meaning that they will
be restricted to those participants that completed a
minimum of three sessions in the intervention group.
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The primary outcome, i.e. reduction in symptoms of de-
pression from baseline to the 3 months follow-up, will be
analyzed using a linear regression approach to analysis of
covariance (ANCOVA) with the follow-up value of the
outcome as the dependent variable and treatment and
baseline value of the outcome as the independent vari-
ables. Secondary outcomes that were measured more than
twice will be analyzed using linear mixed models for fixed
(e.g. treatment) and random effects (e.g. patient). These
models are superior for the analysis of longitudinally cor-
related data and can optimally deal with missing values
[71]. In these analyses, a treatment*time variable indicat-
ing the magnitude of the effect of the intervention on the
change of the outcome variable will be included as an in-
dependent variable. If important baseline differences exist
in prognostic important variables, despite randomization,
we will adjust the analyses by including variables as covar-
iates in additional analyses. Potential baseline differences
will be reexamined before the per protocol analyses. Di-
chotomous outcome variables measured more than twice
will be analyzed using generalized linear mixed models
(mixed-effects logistic regression).
All effect parameters will be supplied with a 95% con-
fidence interval. Statistical significance level will be set
at 0.025, one-sided, as appropriate with the chosen non-
inferiority design.
Fig. 2 Screenshot from the ‘DE-free’ application
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EMA data of real time momentary ratings will be
examined in a bivariate vector-autoregressive Bayesian
dynamic analysis and related analytic approaches to
model the time structure of the data [Krone in prepar-
ation 2016; Krone submitted]. Feasibility and tolerability
of EMA assessment by participants will be examined by
assessing how many participants will be able to complete
at least 70% of the EMA ratings. Based on the literature
we will exclude participants with 30% or more missing
on the EMA ratings (Krone in preparation, [74, 75]).
Additional analysis
Economic outcomes
The cost-effectiveness and cost-utility of blended care will
be studied from a societal perspective, using a time hori-
zon of 12 months. To determine the cost-effectiveness of
both treatments, we will estimate costs in both treatment
groups. To calculate the total direct medical costs we will
estimate the resource use. The resource use will be valued
according to the Dutch guidelines for cost studies [67].
Costs of blended care will be estimated by true re-
sources used. Medication use will be valued based on
costs a provided by The National Health Care Institute
(Zorginstituut Nederland, ZIN). Total costs for both in-
terventions will be summed-up over the 12-month
study period. An incremental cost effectiveness ratio
(ICER) will be calculated using the primary measure of
effect: HDRS-17. In addition, a secondary analysis will
be performed using the number of patients with a re-
sponse as defined under secondary outcomes. In order to
be able to compare the effects of blended care to other
health care interventions, also a cost-utility analysis will be
done; using EQ-5D defined utilities. Bootstrapping will be
performed to depict the 95% confidence intervals sur-
rounding the cost effectiveness, and cost utility ratios.
Cost-effectiveness planes will be plotted in order to repre-
sent the cost-effectiveness graphically.
Discussion
There is a need to investigate accessible ways to offer
psychological treatment in general practice as both GPs
and patients prefer psychological treatment [21–23].
However, barriers to psychological treatment in general
practice such as time constraints and lack of experience
of the GP (28–30), result in GPs prescribing pharmaco-
logical treatment even as a first step [76]. This
contrasts sharply with the guidelines recommending
non-pharmacological treatment as the first step [12, 13]
and is unwanted in view of the side effects, poor adher-
ence, and long-term use after remission associated with
antidepressant use [77–79]. Blended care interventions
may provide GPs a feasible instrument to offer struc-
tured psychological treatment.
The current paper presents the design of a pragmatic
non-inferiority trial to study the effectiveness and cost-
effectiveness of a blended behavioral activation treat-
ment for depressive symptoms and disorders in general
practice.
While previous studies mainly used online psycho-
logical interventions based on cognitive behavioral ther-
apy (CBT) [28, 32, 80], behavioral activation has been
shown as effective and more cost-effective compared to
CBT(50). In addition, it has been experienced as less
complicated and more accessible to patients and thera-
pists [81]. MHWs can learn the technique required
quickly and its effectiveness is comparable to behavioral
activation delivered by more specialist staff with more
training [49]. It is expected that blended behavioral acti-
vation will provide an accessible and easier way to pro-
vide psychological treatment in general practice.
To our knowledge, this is the first trial of blended care
based on behavioral activation in general practice pro-
vided by patients’ own GP or MHWs including assess-
ments of real-time experiences during treatment by the
EMA. An important strength of this trial is that it is
conducted in routine general practice. Patients are re-
cruited and coached by their own GPs and MHWs dur-
ing treatment, hereby mirroring routine general practice
and increasing the study’s generalizability. Another
strength is that the EMA has the advantage of reducing
memory distortions compared to conventional question-
naires. It gives insight into actual experiences during
treatment [82]. In future, knowledge of patients’ real-
time experiences may enable the development of more
personalized blended care for depression [65]. This ran-
domized controlled trial will show whether a blended
behavioral activation treatment is a non-inferior treat-
ment strategy for patients with depressive symptoms
and depressive disorder in general practice.
Additional file
Additional file 1: Questionnaire overall service satisfaction; i.e. satisfaction
with treatment, recommendation of treatment, satisfaction about
effectiveness of treatment and willingness to repeat treatment if needed.
(DOCX 1224 kb)
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